An article titled “CoreValve receives first TAVR valve-in-valve indication” (published April 1, 2015) misstated the CoreValve System’s approval history. It received Food and Drug Administration approval for TAVR performed on native aortic valves in January 2014 in patients at “extreme risk,” and in June 2014 for those at “high risk” for surgical aortic valve replacement.
